MELBOURNE, Australia, Jan. 17, 2014 /PRNewswire/ --
Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit
First Phase III trial in metastatic pancreatic cancer to report three year survival rates[1]
New standard of care for patients with......
More...